[GOLD 2026: implications for COPD care in Sweden].

Authors

Nikolaos Lazarinis, Hamid Akbarshahi, Anne Lindberg, Andrei Malinovschi, Magnus Nisell, Lowie E G W Vanfleteren, Magnus Sköld

Published in

Lakartidningen. Volume 123. Oct 21, 2026. Epub Oct 21, 2026.

Abstract

The 2026 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report introduces major changes with likely implications for the treatment of chronic obstructive pulmonary disease (COPD) in Sweden. Disease stability and disease control are defined as treatment goals for all patients, irrespective of disease severity. The document highlights underdiagnosis of COPD and places greater emphasis on early detection through active case-finding, structured follow-up of disease activity, and systematic assessment of multimorbidity. Extended risk-assessment criteria at diagnosis mean that a single moderate exacerbation is now sufficient to place a patient in GOLD group E. The treatment strategies outlined in GOLD 2026 largely align with the Swedish Medical Products Agency recommendations from 2023, but to fully implement GOLD 2026 in Swedish clinical practice, the current recommendations need to be revised in light of the new evidence.

PMID:
42904526
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.